Fig 1: GSEA identified ADAMTS14-related signaling pathways in TCGA dataset. (A) INSULIN signaling pathway. (B) MTOR signaling pathway. (C) PPAR signaling pathway. (D) Renal cell carcinoma signaling pathway. (E) Renin–angiotensin system signaling pathway. (F) All of these five significantly enriched signaling pathways.
Fig 2: Immunohistochemical staining of ADAMTS14 and SLC13A5 in subchondral bone from patients with KBD and OA. (A,B), the expression of ADAMTS14 in subchondral bone from patients with KBD and OA, respectively (magnification: ×40). (C,D), The expression of SLC13A5 in subchondral bone from patients with KBD and OA, respectively (magnification: ×40). The red arrows represent the positively stained cells.
Fig 3: Validation of the protein expression levels of ADAMTS14 by immunohistochemistry in ccRCC tissue specimens. (A, B) Negative expression of ADAMTS14 in adjacent normal tissue specimens of ccRCC patients. (C, D) Low expression of ADAMTS14 in ccRCC tissues. (E, F) Medium expression of ADAMTS14 in ccRCC tissues. (G, H) High expression of ADAMTS14 in ccRCC tissues; scale bar = 50 μm.
Fig 4: Associations between ADAMTS14 and (A) immune infiltrations, (B) tumor microenvironment, and (C) methyltransferase in TCGA dataset.
Fig 5: Prediction of ADAMTS14-related immune responses of immunotherapy in ccRCC patients. (A) Distribution of ADAMTS14 expression in pan-cancer immune subtypes in TCGA dataset. (B) Distribution of ADAMTS14 expression in CTLA4 scores by TCIA dataset. (C) Distribution of ADAMTS14 expression in TIDE scores by TIDE dataset. (D) Distribution of ADAMTS14 expression in T-cell dysfunction scores by TIDE dataset. (E) Distribution of ADAMTS14 expression in MSI scores by TIDE dataset. ***p < 0.001.
Supplier Page from Abcam for Anti-ADAMTS14 antibody